Gene
therapy breakthrough wins world's largest vision award
Send a link to a friend
[September 05, 2018]
LISBON (Reuters) - Seven scientists in the
United States and Britain who have come up with a revolutionary gene
therapy cure for a rare genetic form of childhood blindness won a 1
million euro ($1.15 million)prize on Tuesday, Portugal's Champalimaud
Foundation said.
|
Established in 2006, the annual award for work related to vision is
one of the world's largest science prizes, more than the latest 9
million Swedish crown ($987,000) Nobel Prize in Physiology or
Medicine.
"This is the first, and still only example of successful gene
therapy in humans that corrects an inherited genetic defect and is
therefore a milestone in medical therapeutics," said Alfred Sommer,
Dean Emeritus of the Johns Hopkins Bloomberg School of Public Health
and chairman of the award jury.
One of those honored, Michael Redmond of the National Eye Institute
in Maryland, had traced the cause of the disease, Leber congenital
amaurosis (LCA), to a mutated gene.
Three cooperating research teams later managed to replace the gene
in the eye, restoring vision to treated children and adults with one
form of LCA and "enabling the entire field of gene therapy for human
disease", the foundation said.
[to top of second column] |
These teams are comprised of U.S. scientists Jean Bennett and Albert
Maguire; Samuel Jacobson and William Hauswirth; and Britons Robin
Ali and James Bainbridge.
Their gene augmentation therapy involved the delivery of healthy
genes using engineered harmless viruses, described by the foundation
as "an elegant solution".
The foundation, which focuses on neuroscience and oncology research
at its Lisbon base, was set up at the bequest of Portugal's late
industrialist Antonio Champalimaud who died in 2004. The first
vision prize was awarded in 2006.
(Reporting by Andrei Khalip; Editing by Alison Williams)
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |